1,4-Ditert-butylimidazolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1,4-Ditert-butylimidazolidine
• 英文别名: 1,4-ditert-butylimidazolidine
• 化学式: C₁₁H₂₄N₂
• 分子量: 184.32
• InChiKey: DQXJUDSHCBDAFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• BISARYL METALLOCENES AND USE THEREOF TO PRODUCE POLYOLEFINS
  申请人：Equistar Chemicals, LP

  公开号：US20150284418A1

  公开（公告）日：2015-10-08

  The present disclosure provides metallocene catalysts for use in polymerization processes. Such catalysts may be used to generate polymers with low branching and high molecular weights. Also, the present disclosure provides methods of bimodal polymerization resulting in a duality of average molecular weight polymers being simultaneously produced. In the system, the size of the polymers produced can be controlled by modifying the type and amount of catalyst activator.

  本公开提供了用于聚合过程中的茂金属催化剂。这些催化剂可用于生成支链少、分子量高的聚合物。此外，本公开提供了双峰聚合的方法，导致同时产生两种平均分子量聚合物。在该系统中，通过修改催化剂活化剂的类型和数量，可以控制所产生聚合物的大小。
• CATALYST PERFORMANCE IN PROPYLENE EPOXIDATION
  申请人：Lyondell Chemical Technology, L.P.

  公开号：US20160297782A1

  公开（公告）日：2016-10-13

  The present disclosure relates to a method of epoxidizing an olefin to form an epoxide, the method comprising contacting an alkene (C≦12) or aralkene (C≦12) with a titanium silica catalyst, a peroxide, a buffer, and one or more organic solvents in a reaction mixture, wherein the one or more organic solvents comprise a first organic solvent selected from: R 1 —OH  (I), R 2 —CN  (II), R 3 —C(O)—R 4 (III) or R 5 —O—R 6 (IV) wherein: R 1 is alkyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) or a substituted version of any of these groups; R 2 is alkyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) or a substituted version of any of these groups; R 3 is hydrogen, alkyl (C≦6) or substituted alkyl (C≦6) ; and R 4 , R 5 , and R 6 are each independently selected from alkyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) or a substituted version of any of these groups, or are taken together are alkoxydiyl (C≦12) , alkanediyl (C≦12) , substituted alkoxydiyl (C≦12) or substituted alkanediyl (C≦12) .

  本公开涉及一种环氧化烯烃形成环氧化物的方法，该方法包括将烯烃(C≦12)或芳基烯烃(C≦12)与钛硅催化剂、过氧化物、缓冲剂和一个或多个有机溶剂接触于反应混合物中，其中一个或多个有机溶剂包括从以下第一有机溶剂中选择的：R1—OH  (I)、R2—CN  (II)、R3—C(O)—R4(III)或R5—O—R6(IV)，其中：R1为烷基(C≦12)、芳基(C≦12)、芳基烷基(C≦12)或这些基团的取代版本；R2为烷基(C≦12)、芳基(C≦12)、芳基烷基(C≦12)或这些基团的取代版本；R3为氢、烷基(C≦6)或取代烷基(C≦6)；且R4、R5和R6各自独立地选择自烷基(C≦12)、芳基(C≦12)、芳基烷基(C≦12)或这些基团的取代版本，或者一起选自烷氧基二基(C≦12)、烷基二基(C≦12)、取代烷氧基二基(C≦12)或取代烷基二基(C≦12)。
• DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS
  申请人：WILLIAM MARSH RICE UNIVERSITY

  公开号：US20160185791A1

  公开（公告）日：2016-06-30

  In one aspect, the present disclosure provides new analogs of uncialamycin of formulae (I) and (II). The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates comprising the compounds of formulae (I) and (II).

  在某个方面，本公开提供了式（I）和（II）的新的uncialamycin类似物。本公开还提供了获得uncialamycin及其类似物的新型合成途径。此外，本公开还描述了uncialamycin及其类似物的使用方法。在另一方面，本公开提供了包含式（I）和（II）化合物的抗体药物偶联物。
• Coumarin based Hsp90 inhibitors with urea and ether substituents
  申请人：University of Kansas

  公开号：US10030006B2

  公开（公告）日：2018-07-24

  Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.

  提供了以下式子的化合物： 其中：提供了 R1-R4、X1、Y1 和 A 如本文所定义的化合物。还提供了这些化合物的药物组合物。在某些方面，这些化合物可用于治疗疾病或紊乱。在某些实施方案中，疾病或紊乱是增殖性疾病，如癌症。
• Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
  申请人：WILLIAM MARSH RICE UNIVERSITY

  公开号：US10233192B2

  公开（公告）日：2019-03-19

  In one aspect, the present disclosure provides new analogs of uncialamycin. The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates which may be used to treat cancer or another disease or disorder.

  一方面，本公开提供了新的安卡拉霉素类似物。本公开还提供了获得安卡拉霉素及其类似物的新合成途径。此外，本公开还描述了使用安卡拉霉素及其类似物的方法。在另一方面，本公开提供了可用于治疗癌症或其他疾病或紊乱的抗体-药物共轭物。